Financing, Organisation and Delivery of Health Care

Achieving productivity and efficiency in health care depends on policies that are based on solid evidence and that take full account of the needs of patients, whom health care is intended to benefit. Key OHE projects include research and analysis of options for value based pricing (VBP) for pharmaceuticals, patient reported outcome measures (PROMs), productivity in the NHS, and competition in the NHS.  The report of the 2011 OHE Commission on Competition in the NHS was released in 2012 and is available for download here.

Health Technology Assessment Methods and Processes

Health technology assessment, or HTA, is intended to assist policy makers in determining which health expenditures offer the greatest value. The OHE has a variety of projects underway on HTA and has recently published a thorough analysis of multiple criteria decision analysis (MCDA), applicable in any country. Research focused primarily on the UK's National Institute for Health and Care Excellence (NICE) and the NHS includes, for example: how best to capture patients’ preferences using the EQ-5D instruments and time-trade off (TTO) methods; and how NICE makes decisions and how those decisions affect access to health care.

With City University London and Abacus International, OHE has created HTAinSite, a comprehensive database of decisions taken by NICE since its inception in 1999.

Economics of the Pharmaceutical and Life Science Industries

Private industry plays an essential role in innovation in all aspects of health care, interacting with both public- and charity-funded research sectors to realise the benefits of innovation worldwide. OHE’s recent research has included, for example, analysis of how best to stimulate R&D for new antimicrobials and for orphan/neglected diseaseas, in both developed and the developing countries, and ensure access to needed new medicines in the latter. The effects of pricing and reimbursement on innovation remains a core area of research.